Lack of initial response to imatinib might indicate need to switch to dasatinib.
Researchers reported long-term follow-up results from the phase 3 RERISE study, which assessed the efficacy of radotinib compared with imatinib for CML treatment.
Asciminib appeared to have clinical activity in a population of heavily pretreated patients with chronic myeloid leukemia, including those with a T315I mutation.
Results of LAST, the largest study on TKI discontinuation, support using patient-reported outcomes when monitoring remission and symptoms in patients who discontinue TKI therapy.
Patients received 50 mg dasatinib daily and demonstrated 2-year rates of overall and event-free survival of 100%.